| Alza Corporation Patent applications |
| Patent application number | Title | Published |
|---|
| 20120070496 | ANTIDEPRESSANT DOSAGE FORM - A dosage form having sustained-release or controlled-release properties for delivering 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol from the dosage form over an extended period of time in a therapeutically responsive dose to produce antidepressant therapy. | 03-22-2012 |
| 20110229533 | EXTENDED RELEASE DOSAGE FORM - A membrane system comprising an interior wall, a fluid-permeable exterior wall surrounding the interior wall and an internal compartment defined by the membrane system, wherein fluid permeability of the interior wall is responsive to osmolarity of an osmotic core within the internal compartment are disclosed. A controlled release dosage form comprising the membrane system and a process for delivering an osmotically active formulation from an osmotic pump over an extended period of time are also disclosed. | 09-22-2011 |
| 20100221305 | Formulations for coated microprojections containing non-volatile counterions - The invention provides for a formulation for coating one or more microprojections which reduces or minimizes the loss of counterions from the coating in order to achieve a pH-stabilized formulation. | 09-02-2010 |
| 20100160895 | Apparatus and Method for Transdermal Delivery of Parathyroid Hormone Agents - An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the PTH-based agent is contained in a biocompatible coating that is applied to the microprojection member. | 06-24-2010 |
| 20100152649 | Apparatus and method for transdermal delivery of parathyroid hormone agents - An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the PTH-based agent is contained in a biocompatible coating that is applied to the microprojection member. | 06-17-2010 |
| 20100152242 | Transdermal Electrotransport Delivery Device Including an Antimicrobial Compatible Reservoir Composition - A transdermal electrotransport drug delivery device having an anode, a cathode and a source of electrical power electrically connected to the anode and the cathode. At least one of the anode and the cathode includes an electrode and a reservoir comprised of a housing composed of a polymeric material and an aqueous medium in contact with the housing. The aqueous medium includes (i) a drug or an electrolyte salt or a mixture thereof, (ii) propylene glycol, and (iii) an antimicrobial agent in an amount sufficient to inhibit microbial growth in the aqueous medium. The propylene glycol prevents the antimicrobial agent from being adsorbed by other materials used in the construction of the delivery device. A process for preparing a transdermal electrotransport drug delivery device is also provided. | 06-17-2010 |
| 20100119568 | Apparatus and method for transdermal delivery of parathyroid hormone agents - An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the PTH-based agent is contained in a biocompatible coating that is applied to the microprojection member. | 05-13-2010 |
| 20100076368 | Electrotransport Delivery Device Having Improved Safety and Reduced Abuse Potential - An electrotransport device for delivering one or more therapeutic agents through the skin includes electrodes for contacting the skin, at least one electrode containing the agent, a power source for generating electrical current (I | 03-25-2010 |
| 20100004583 | Hydrophobic Circuit Board Coating of Electrotransport Drug Delivery Devices - The present invention encompasses an improved electrotransport drug delivery device utilizing a hydrophobic modifier to prevent moisture condensation. Use of a hydrophobic modifier increases the hydrophobicity of coated parts of the device, reducing the amount of moisture uptake of the device during storage in a high humidity environment. In a further embodiment, a package of the improved electrotransport drug delivery device is provided. In addition, a method of reducing moisture condensation to an electrical device and a method of preserving an electrical device for an electrotransport drug delivery device are provided. | 01-07-2010 |
| 20090312689 | Adjustable Current Electrotransport Fentanyl Delivery Device - A transdermal electrotransport fentanyl delivery system having relatively stable fentanyl flux. The system has a controller that controls a current through a donor reservoir wherein the current is generally changed nonlinearly with time with conductance or resistance as a factor to result in a relatively stable fentanyl flux. | 12-17-2009 |
| 20090275877 | Method of Enhancing Electrotransport Polypeptide Flux By Amino Acid Substitution with Histidine - Methods of modifying polypeptide drugs in order to enhance their transdermal electrotransport flux are provided. The polypeptide is modified by substituting a histidine residue (His) for one or more glutamine (Gln), threonine (Thr) and/or asparagine (Asn) residue(s). The His for Gln substitution is particularly preferred from the standpoint of retaining biological activity of the parent polypeptide. Compositions containing the modified polypeptide, which are useful for transdermal electrotransport delivery, are also provided. | 11-05-2009 |
| 20090264855 | Method and Device for Transdermal Electrotransport Delivery of Fentanyl and Sufentanil - The invention provides an improved electrotransport drug delivery system for analgesic drugs, namely fentanyl and sufentanil. The fentanyl/sufentanil is provided as a water soluble salt (eg, fentanyl hydrochloride) dispersed in a hydrogel formulation for use in an electrotransport device ( | 10-22-2009 |
| 20090221621 | Methods of Reducing Alcohol-Induced Dose Dumping for Opioid Sustained Release Oral Dosage Forms - Disclosed are methods of sustained release administration of opioids, including but not limited to hydromorphone and oxycodone, that exhibit improved properties with respect to co-ingestion with aqueous alcohol. | 09-03-2009 |
| 20090186147 | Transdermal drug delivery devices having coated microprotrusions - Methods are provided for preparation of a coating on one or more microprojections of a microprojection array using wetting agents either as a pretreatment of the microprojection surfaces or incorporated in the coating formulation along with the active agent. | 07-23-2009 |
| 20090183673 | Method and apparatus for coating skin piercing microprojections - An Apparatus and method are provided for selectively applying an agent-containing liquid coating to extremely tiny skin piercing microprojections ( | 07-23-2009 |
| 20090143724 | Microprojection Array Immunization Patch and Method - Skin patches ( | 06-04-2009 |
| 20090136554 | Transdermal sustained release drug delivery - Provided herein are microprojections and microprojection arrays for delivering biologically active agents. Also provided herein are compositions suitable for coating such microprojections and microprojection arrays. | 05-28-2009 |
| 20090105634 | Anodic Reservoir for Electrotransport of Cationic Drug - An electrotransport system for delivery of a cationic drug. The system has a donor anodic reservoir having an insoluble biocompatible polymeric anion source embedded in the reservoir. The anion source has precipitating anions that can precipitate out metal ions generated from sacrificial metal of the anode during electrotransport. | 04-23-2009 |
| 20090087484 | Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules - A formulation and dosage form for enhancing the bioavailability of orally administered hydrophilic macromolecules includes a permeation enhancer, a hydrophilic macromolecule, and a carrier such as a nonionic surfactant that exhibits in-situ gelling properties. The formulation is delivered within the GI tract as a liquid having at least some affinity for the surface of the GI mucosal membrane. Once released, it is believed that the liquid formulation spreads across one or more areas of the surface of the GI mucosal membrane, where the carrier of the formulation then transitions into a bioadhesive gel in-situ. As a bioadhesive gel, the formulation presents the hydrophilic macromolecule and the permeation enhancer at the surface of the GI mucosal membrane at concentrations sufficient to increase absorption of the hydrophilic macromolecule through the GI mucosal membrane over a period of time. A dosage form incorporates the formulation and may be designed to provide the controlled release of the formulation within the GI tract over a desired period of time. | 04-02-2009 |
| 20090075323 | Static Diffusion Cell for Diffusion Sampling Systems - A new design for a static diffusion cell for use in a diffusion sampling apparatus to be used in conjunction with automated or manual sampling is disclosed. The diffusion cell of present invention provides to an improved and efficient diffusion assay system. | 03-19-2009 |
| 20090036822 | Electrotransport Agent Delivery Method and Apparatus - An electrotransport device for delivering or sampling an agent through a body surface by electrotransport, the device having a housing including an upper, exterior housing portion and a lower housing portion, the housing enclosing electronic components, and at least one hydratable or hydrated reservoir containing water or an at least partially aqueous solution of the agent. At least a portion of the housing is composed of an ethylene-octene copolymer. | 02-05-2009 |
| 20080226687 | Drug delivery and method having coated microprojections incorporating vasoconstrictors - A device and method are provided for percutaneous transdermal delivery of a biologically active agent. The coating formulation containing the biologically active agent and a vasoconstrictor is applied to the skin piercing elements using known coating techniques and then dried. The device is applied to the skin of a living animal, causing the microprojections to pierce the stratum corneum and to deliver an effective dose of the biologically active agent and vasoconstrictor to the animal. | 09-18-2008 |
